Transaction DateRecipientSharesTypePriceValue
13th July 2020Walter V Klemp79,227Exercise of derivative$0.00
13th July 2020Walter V Klemp19,292Payment by withholding$0.86$16,513.95
Moleculin Biotech
Moleculin Biotech logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms.

Ticker: MBRX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1659617
Employees: 9
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $17 M (55%)
Other Assets, Current: $436 Th (-17%)
Assets, Current: $20 M (46%)
Property, Plant and Equipment, Net: $238 Th (-24%)
Assets: $31 M (24%)
Accounts Payable, Current: $2 M (-10%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $4 M (4%)
Liabilities: $16 M (62%)
Common Stock, Value, Issued: $60 Th (30%)
Common Stock, Shares, Issued: $60 M (32%)
Additional Paid in Capital, Common Stock: $66 M (20%)
Retained Earnings (Accumulated Deficit): $51 M (0%)
Stockholders' Equity (Parent): $16 M (0%)
Liabilities and Equity: $31 M (24%)
Research and Development: $3 M (-49%)
General and Administrative Expenses: $2 M (-52%)
Operating Income/Loss: $5 M (-50%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
Moleculin Biotech: Some Recent Momentum On A Beaten-Down Name

9th February 2021